As the United States marks the tenth anniversary of the establishment of a biosimilars pathway, many experts express frustration that the US lags behind
Europe. A new white paper from Matrix Global Advisors carefully examines the US and European biosimilars markets and finds that the comparison between the markets is nuanced.
“…net employment at ESOPs climbed over 60% during 2001-2011 vs. no change elsewhere, concludes research by Alex Brill, CEO of consulting firm Matrix Global Advisors.”
Matrix Global Advisors (MGA) today released a new report, “Shared Savings Demonstration for Biosimilars in Medicare: An Opportunity to Promote Biologic Drug Competition,” by MGA founder and CEO Alex Brill. The report identifies a unique opportunity in Medicare Part B to boost biosimilar utilization through the establishment of a shared savings demonstration model administered by the Centers for Medicare & Medicaid Services Innovation Center.
“We want the program to work and I think that sadly what we’re seeing is that the program is working quite well. And I say sadly because we are seeing tens of millions of people process through that system and we’re going to continue to see that I think for the next few weeks as the backlogs in certain states get worked through…”
“‘That could help accelerate the rebound if we can just kind of mothball the economy and then turn back on the same economy with the same manager-employee relationship,” said Alex Brill, a resident fellow at the right-leaning American Enterprise Institute.”
